CHARLOTTE, N.C., April 2, 2014 /PRNewswire/ -- SonaCare Medical, LLC, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, starts 2014 with strong first quarter device sales. SonaCare Medical sold two Sonablate® HIFU devices for the non-invasive treatment of prostate cancer in the international market and two Sonatherm® laparoscopic surgical soft tissue ablation systems in the United States during the quarter.
"We are excited to add two premier academic institutions located in the New York metro area and Southern California to the list of institutions that are leading the way in ablation technologies," said Mike Klein, Chief Executive Officer for SonaCare Medical. Klein continued, "These two new institutions will work alongside with our other international academic partners to lead the way in building the next generation of surgical focused ultrasound ablation, which we call SonaSurgery."
"Continuing on the momentum from our four Sonablate HIFU device sales during Q4 of 2013, we were able to start with a strong first quarter of this year. Physician demand for a partial gland or focal solution continues to be one of the hottest topics at all the urology conferences we have attended and will certainly be the most anticipated portion of the upcoming European Urology Conference," stated Alex Gonzalez, Vice President of Operations for SonaCare Medical. "The additional sales of the two FDA 510(k) cleared Sonatherm® laparoscopic HIFU soft tissue ablation devices to top tier academic institutions further punctuate our successful transition into a minimally invasive ablation platform company," added Gonzalez.
SonaCare Medical will showcase its HIFU platform at the 29th annual European Association of Urology (EAU) Congress, in Stockholm, Sweden from April 11-15, 2014. (Booth: 11:39)
About SonaCare Medical SonaCare Medical, LLC a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C. Additional information may be found at www.SonaCareMedical.com.
SOURCE SonaCare Medical, LLC